
Building CoFormBio https://www.teapawt.org/t.co/WL2biDcrtV | Ex-EQRx (a16z, Arch, GV) - sold to $RVMD, Ex-Scipher (Khosla), Ex-Goodwin | China expert | ☘️ Celtics | 我叫王明 杰 | سام
Los Angeles (via Boston)
Joined October 2010
- Tweets2.3K
- Following1.1K
- Followers1.6K
- Likes8.2K
Sam Davis retweeted
I don't understand.
They used a bunch of open/closed-source tools to screen a tiny virtual library and are complaining they didn't generate a working drug?
Those are two entirely different design objectives. What does working even mean in this context?
I can't believe this is the state of discourse. Using computers to make medicines has been and will continue to be central to the art.
Small molecule tools are lagging behind biologics. They'll catch up. I think everyone knows this.
Non-story.
‘“That’s complete BS,” said Jeff Leiden, executive chairman of Vertex Pharmaceuticals. Vertex has used roughly 50 AI companies to comb through its data set of 10,000 drug compounds, Leiden said. Not one managed to generate a working drug.’ 👇🏼
wsj.com/tech/ai/silicon-vall…
Sam Davis retweeted
25 years after the human genome, new drug targets are still scarce: Since 2000, 312 new targets have been added, an 84% increase, but that works out to only about 12–15 a year.
Source: nature.com/articles/s41573-0…
Sam Davis retweeted
Latest quarterly sales for Mounjaro and Ozempic was ~$24B. So TODAY, it is a $100B market. And this is excluding all the old GLP-1s for T2D.
No Big Pharma will ever say NO to a $100B market. It may be a "no" now, but it can change
Sam Davis retweeted
The power of AI, folks.
This is freaking huge: For the first time, a AI-assisted personalized mRNA cancer treatment has succeeded in a Phase 3 trial.
Moderna and Merck sequence each patient’s tumor and compare it with their healthy DNA. AI then helps identify which of the tumor’s mutations are most likely to trigger an immune response.
From those targets, Moderna produces an individual mRNA treatment encoding up to 34 neoantigens, The earlier Phase 2 trial followed patients with surgically removed high-risk melanoma for five years:
- 68.8% remained cancer-free, compared with 49.1% on Keytruda alone
- 49% lower risk of recurrence or death
- 59% lower risk of distant metastasis or death
Now the much larger Phase 3 trial involving 1,137 patients has also succeeded.
Absolutely incredible. Dario was right: cancer will be cured in just a few years!
Sam Davis retweeted
Today, we announced a multi-part clinical development and regional commercialization collaboration with @BeOneMedicines
Read more: revmed.com/media/news/13306/…
He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California? — via @BostonGlobe trib.al/8O0lYg7
Sam Davis retweeted
APAC led biopharma licensing upfronts in H1 2026 with $5.8B, compared with $2.8B for the U.S. and $600M for EMEA. APAC has already reached nearly 80% of its 2025 full-year total ($7.4B).
Sam Davis retweeted
This is also sorta mindblowing....
The product is a beachhead in Anthropic’s larger battle for the future of biology. The firm has ambitions so big they would seem caricaturish were it not for its financial means. A month ago Anthropic said it had reached annualized sales of $42 billion — about as much as the drug giant GSK — and that it is valued, based on a $65 billion funding round, at $965 billion, far more than any health care company except Eli Lilly.
statnews.com/2026/06/30/anth…
Sam Davis retweeted
NEW: Anthropic announces it is developing its own preclinical drug programs
No specifics provided beyond a focus on neglected diseases
"To build the right models, products and tools, we need to live it along with all of you," Eric Kauderer-Abrams, Anthropic life sci head, says
Sam Davis retweeted
This tracks -- something I've noticed though (at least on the VC-backed side) is that these ex China NewCos are heavily concentrated around Series A/launch rounds.
China-origin has been ~1/3 of Series A capital in 2026 vs ~0% at Series C+ YTD
Sam Davis retweeted
Protectionism will not work in #biotech (it certainly won't rescue companies that have no product and whose shares are down 98% from their highs).
What it will do is raise costs, slow innovation, and ultimately cost lives.
The United States should focus on strengthening its competitive advantages:
🔬 Invest aggressively in scientific R&D, startups, and clinical trials.
💊 Launch a modern "Manhattan Project" to secure domestic #manufacturing of critical pharmaceutical ingredients and medicines.
✂️ Cut unnecessary regulations while maintaining rigorous safety standards.
🧲Improve immigration laws to retain the world's best #scientific talent.
🌎 China, Latin America, India, Europe: competition is everywhere. It's called capitalism.
America wins not by building walls around innovation, but by out-innovating everyone else.
Sam Davis retweeted
Replying to @adamfeuerstein @ADeAngelis_bio
We will not ignore innovation anywhere while we figure all this out. I didn’t call for a ban on Chinese drugs because it is not the right way to deal with it. Will just force innovation to European Pharma. We should have the discussion on how to advantage USA innovators in a free market, without slowing down cures and hurting patients, without forcing innovation to the EU. Is a tricky balance, but we should lean into rewarding and speeding up USA innovators, fast, now, yesterday, and making sure we have economic incentives aligned toward long-term investment.
Sam Davis retweeted
biotech venture capital has never been more risk-off, consensus-driven, and allergic to the very risk the industry was built on
Sam Davis retweeted
$BBIO Neil Kumar at #STATBreakthrough laying in to investors and executives building companies just to sell to pharma
“You can't take a contrarian bet, that's why we have… 150 PDL1 ones, 300 GlP-1s, like everyone's doing the same stuff”
Sam Davis retweeted
Many people in traditional pharma and biotech have never heard of “parent-founders.”
When a child is diagnosed with a rare pediatric disease, many parents don’t wait for someone else to act. They found their own companies — FAMCOs (family-founded companies) — with one singular mission: develop a cure for their child and others like them. These FAMCOs are operating at the same intensity and scientific rigor as traditional biotech teams… yet they’ve largely flown under the radar.
Why? Because many ultra rare diseases have such small patient markets that traditonal pharma sees little economic incentive to invest. Over 90% of rare diseases still have no FDA-approved treatment.
At @1000cures, we’re working to change that.
We exist to break down the systemic barriers these parent-founders face and provide them the capital, infrastructure, and operational support they need to succeed.
It’s time to shine a light on this powerful, under-recognized force in drug development — and accelerate the cures their children deserve.
If you’re a parent-founder, investor, or anyone working in rare disease, we’d love to connect!
Sam Davis retweeted
Immunology combination studies from Morgan Stanley ahead of DUET data next week.
These are mainly coformulations of established drugs, it would be more intriguing to see novel MOAs added to an IL23 backbone.
Sam Davis retweeted
NewCo & China Pharma licensing deal
Newly launched U.S. startup Tortugas Neuroscience has raised $106 million to advance a Phase II neuroscience portfolio licensed from China’s Hansoh and Japan’s Eisai. tortugasneuro.com/tortugas-n…
Assets contributed by 🇨🇳Hansoh include a D2/D3 partial agonist–5‑HT2A antagonist for schizophrenia and a GABAA positive allosteric modulator for tinnitus.
Eisai adds two additional Phase II programs, a GAT‑1 inhibitor for focal epilepsy and a PDE9 inhibitor for reversible encephalopathies.








































